Bulky Advanced Ovarian Cancer: Primary Debulking or Neoadjuvant Therapy
A 68-year-old woman presents with 3 weeks of bloating, early satiety, and increasing abdominal girth. CT shows a 9 cm complex pelvic mass, omental caking, moderate ascites, and a 1.5 cm umbilical nodule; there is no liver parenchymal disease or hydronephrosis. CA-125 is 1,240 U/mL, albumin 3.1 g/dL, and ECOG performance status is 2. She lives alone and says she wants 'everything done at once.' Paracentesis confirms high-grade serous carcinoma. The community hospital where she was diagnosed has offered surgery next week; the regional cancer center offers diagnostic laparoscopy with possible neoadjuvant chemotherapy. She had a myocardial infarction 2 years ago with drug-eluting stents and remains on aspirin plus clopidogrel.
1. How do you choose between primary cytoreduction and neoadjuvant chemotherapy in this patient, and how does her antiplatelet therapy influence the decision?
Read the worked answer
This is a resectability and fitness question, not a slogan. Neoadjuvant chemotherapy with interval debulking is non-inferior for survival with less perioperative morbidity, but primary debulking remains preferred when complete resection to no visible residual disease is achievable at acceptable risk.
Factors against upfront surgery here: ECOG 2, hypoalbuminemia, high tumor burden with omental caking and an umbilical (Sister Mary Joseph) deposit, and recent coronary stenting on dual antiplatelet therapy. Complete resection is less likely, and residual disease is the strongest prognostic variable, so an incomplete operation adds morbidity without benefit.
- Assess resectability directly: diagnostic laparoscopy with a validated scoring system (Fagotti/PCI), performed by the surgeon who would actually do the debulking. If complete cytoreduction is not feasible, proceed to neoadjuvant carboplatin/paclitaxel.
- Antiplatelet therapy: interrupting dual therapy within 2 years of stenting risks stent thrombosis. If surgery were chosen, coordinate with cardiology; typically aspirin continues and the P2Y12 inhibitor stops 5-7 days preoperatively. Neoadjuvant chemotherapy defers this problem.
- Nutrition and prehabilitation: dietitian input, consider feeding support before any operation.
Referral to the center that can offer both options is appropriate; the community plan for immediate surgery should not proceed without a resectability assessment.
2. She receives three cycles of carboplatin/paclitaxel. How do you reassess, and what determines whether she goes to the operating room?
Read the worked answer
Reassess with CA-125, CT chest/abdomen/pelvis, and clinical performance status. The endpoint is not 'shrinkage' for its own sake but whether an interval debulking can achieve complete resection in a patient fit enough to recover.
- Responding and fit: proceed to interval debulking, typically 3-4 weeks after cycle 3, with the same objective of no visible residual disease. Total planned chemotherapy is usually six cycles, with the balance given postoperatively.
- Progressing on neoadjuvant therapy (new lesions, rising CA-125, worsening performance status): this defines platinum-resistant disease; surgery will not help and she should switch to a non-platinum regimen or a trial.
- Complete radiological response: surgery is still generally considered, since imaging underestimates residual disease; some centers individualize.
- Persistent unresectable disease at exploration: close and continue systemic therapy rather than performing a maximal-effort resection.
Preoperative assessment should repeat cardiac risk stratification, correct albumin and electrolytes, and confirm that the umbilical deposit will be resected en bloc if present, because leaving it constitutes residual disease.
3. The team raises hyperthermic intraperitoneal chemotherapy at interval debulking, and the patient asks whether the umbilical nodule means she is incurable. How do you answer both?
Read the worked answer
HIPEC: the evidence does not support routine use. In the primary setting, a large randomized trial of HIPEC at cytoreduction in platinum-sensitive stage III disease was negative. A randomized trial of HIPEC at interval debulking after neoadjuvant chemotherapy in stage III disease did show improved progression-free and overall survival, so the only reasonably supported setting is interval debulking after neoadjuvant therapy with complete resection, at a center with experience and appropriate renal and hematologic monitoring. It carries real morbidity, including renal toxicity and anastomotic complications, and should be framed as a center-specific or trial option rather than standard care. It is not indicated for gross residual disease.
The umbilical nodule: it is a metastatic deposit, which makes this stage IV disease. That changes prognosis discussion and the emphasis on systemic therapy, but it does not make surgery futile and does not change the chemotherapy backbone. If cytoreduction is performed, the umbilicus must be excised en bloc; leaving it behind is residual disease. She should hear a realistic statement: this is treatable but not curable, and the goals are延长 survival with good quality of life, control of ascites, and preservation of independence - which is what 'everything done at once' probably means to her.